The platform orchestrates data to evaluate site maturity and performance and provide recommendations for improvement.
- Hidden Sensitive Data Liability: Why Legacy Web Forms Put Life Sciences Organizations At Critical Risk
- A Hierarchy Of Metrics Brings Strategy Into Biopharma's Daily Work
- An End-To-End Automated HTP Platform For Cell Line Optimization
- Here's What You Need To Know About The Access Consortium Pathway
- FDA Draft Guidance On CES Signals More Reliance On Toxicity And PK
- Maximizing The Value Of An Internal Audit Program In Pharmaceutical Quality Operations
- AI Is Not The CMC Revolution You're Looking For, And That's OK
EDITOR'S DESK
-
AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.
AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.
Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.
DeciBio partner Carl Schoellhammer, Ph.D., speaks on the record with Bioprocess Online's chief editor Tyler Menichiello at the 2025 BioProcess International conference in Boston.
Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around.
GUEST COLUMNISTS
-
Hidden Sensitive Data Liability: Why Legacy Web Forms Put Life Sciences Organizations At Critical Risk
Many life science organizations collect sensitive data through outdated web forms, exposing companies to critical vulnerabilities, data breaches, regulatory penalties, and more.
-
A Hierarchy Of Metrics Brings Strategy Into Biopharma's Daily Work
Information now flows faster than organizations can think about it, and without deliberate structure, decision-making becomes reactive rather than reflective.
-
An End-To-End Automated HTP Platform For Cell Line Optimization
Bristol Myers Squibb's high-throughput stable CHO platform produces high-titer, high-quality material in a fraction of the conventional timeline.
-
Here's What You Need To Know About The Access Consortium Pathway
Five nations are collaborating on a work-sharing program to reduce regulatory duplication in drug development.
-
FDA Draft Guidance On CES Signals More Reliance On Toxicity And PK
The technology to measure alternative metrics is vastly improved. Now, FDA joins other regulators in deprioritizing comparative efficacy studies for biosimilars.
-
Maximizing The Value Of An Internal Audit Program In Pharmaceutical Quality Operations
A shrinking FDA and rising supply pressures demand stronger risk management and smarter internal audits. Here’s how pharma can truly “see things as they really are.”
-
AI Is Not The CMC Revolution You're Looking For, And That's OK
Advanced therapy development today is less about big funding, more about frugality. Artificial intelligence unlocks a competitive advantage.
-
Phages As A Pharmaceutical: New EMA Guidance On Antimicrobial Drug Development
The EMA has now issued a draft guidance on quality aspects of phage therapy medicinal products. Rising antimicrobial resistance has renewed interest in bacteriophages to fight pathogens.
BIOPROCESSING WHITE PAPERS
-
Reducing ADC Timelines With Integrated Development And Manufacturing
ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.
-
Perspectives On The Adoption Of Fully Closed Processing1/16/2024
In this study, industry experts share their perspectives and plans related to the implementation of fully closed processing. Explore the drivers and challenges of fully closed processing and more.
-
From CLD To CDMO: Demonstrating A Successful Cell Line Technology Transfer8/5/2024
Explore critical considerations for biopharmaceutical developers and CDMOs during technology transfer as well as a successful transfer and scale-up of a cell line from a CLD platform to a global CDMO.
-
Beyond Traditional Monoclonal Antibodies9/24/2025
New antibody formats present new purification challenges due to novel impurity profiles. New methods and media are required to ensure safe, effective, and scalable manufacturing of these biologics.
-
Suspension Culture Improves iPSC Expansion And Pluripotency Phenotype12/19/2024
Learn about the advantages of 3D suspension culture for iPSC expansion, including enhanced pluripotency and genetic stability. Discover how this technique yields high-quality iPSCs for regenerative cell therapies.
-
Three Key Strategies To Guide Efficient And Effective Recall Management2/18/2025
Discover how to successfully navigate recalls with a digital approach that helps achieve effective recall management, communication, and continuous improvement for brand integrity.
BIOPROCESSING APP NOTES & CASE STUDIES
- Structural Characterization Of GLP-1 Analogues And Formulations Using MMS
- Development To Large-Scale cGMP Production
- A Paradigm Shift From Glass Benchtop Bioreactors
- Bioconversion Of Babassu Mesocarp Flour Into Single-Cell Protein In A Controlled Bioreactor System
- A Non-Viral Workflow For Modifying Primary T Cells
- FDA Releases Draft Guidance To Accelerate Biosimilar Development
- Supporting The Next Generation Of ADCs
- AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
- On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration
- On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing
- On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D.
- Single-Use Standardization Starts At Home
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- mAb Purification: A Two-Step Approach Using A Strong AEX-HIC Mixed-Mode Resin
- Streamlining pDNA: Capacity, Complexity, And Cutting-Edge Solutions
- Are You Keeping Pace With Oligo Synthesis Optimization?
- From Readiness To Results: Unlocking Capacity For Expanding Product Demand
- Accelerating Early Phase Biologics From The Clinic To Commercialization
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 11.26.25 -- How CMC And MSAT Teams Consider PATs
- 11.25.25 -- Improving Sponsor–CMO Collaboration Around Digital Deviations
- 11.24.25 -- Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach
- 11.21.25 -- STREAM Edition: Developing Analytical Methods For Advanced ADCs
- 11.21.25 -- It's Not Just You, Everyone's Talking About OPV